Organization Overview
Alternative names
omidubicel (Omisirge) (2023 NDA)
Anemia, Sickle Cell (Phase 2)
Fractures, Bone (Phase 3)
Hemoglobinopathies (Phase 2)
Hip Fractures (Phase 3)
Hodgkin Disease (Phase 2)
Leukemia (Phase 3)
Leukemia, Myeloid (Phase 3)
Leukemia, Myeloid, Acute (Phase 3)
Lymphoma (Phase 3)
Myelodysplastic Syndromes (Phase 3)
Neoplasms (Phase 3)
Preleukemia (Phase 3)
Syndrome (Phase 3)
Thalassemia (Phase 2)